Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Camptothecin - BlueLink Pharmaceuticals/Calando Pharmaceuticals

Drug Profile

Camptothecin - BlueLink Pharmaceuticals/Calando Pharmaceuticals

Alternative Names: Camptothecin-nanoparticle-cerulean; CRLX 101; Cyclosert-CPT; Cyclosert™-enhanced camptothecin; IT-101; NLG 207

Latest Information Update: 09 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Insert Therapeutics
  • Developer AstraZeneca; BlueLink Pharmaceuticals; Cerulean Pharma; Insert Therapeutics; Massachusetts General Hospital; National Cancer Institute (USA); University of North Carolina
  • Class Antineoplastics; Camptothecins; Drug conjugates; Small molecules
  • Mechanism of Action DNA topoisomerase I inhibitors; Hypoxia-inducible factor-1 alpha inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer; Prostate cancer; Rectal cancer; Renal cell carcinoma; Small cell lung cancer
  • Phase I/II Solid tumours
  • No development reported Breast cancer; Gastric cancer; Non-small cell lung cancer

Most Recent Events

  • 02 Apr 2019 Updated efficacy and adverse events data from a phase Ib/II trial in Ovarian cancer, Fallopian tube or Peritoneal cancer presented at the American Association for Cancer Research Annual Meeting (AACR-2019)
  • 28 Mar 2019 No recent reports of development identified for preclinical development in Breast-cancer(Combination therapy) in USA (IV)
  • 28 Mar 2019 No recent reports of development identified for preclinical development in Breast-cancer(Monotherapy) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top